DNL422 / Denali Therap - LARVOL DELTA

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "Denali expects to submit regulatory applications to begin clinical testing of one to two TV-enabled programs each year over the next three years across its Enzyme TV (ETV), Antibody TV (ATV), and Oligonucleotide TV (OTV) franchises. The most advanced programs include:...DNL111 (ETV:GCase) for Parkinson’s/Gaucher disease;...DNL921 (ATV:Abeta) for Alzheimer’s disease; DNL628 (OTV:MAPT) for Alzheimer’s disease; and DNL422 (OTV:SNCA) for Parkinson’s disease."

IND • Alzheimer's Disease • Parkinson's Disease